$800 Thousand is the total value of Bain Capital Life Sciences Investors, LLC's 34 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 15.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NEWAMSTERDAM PHARMA COMPANYordinary shares | $110,058 | +21.7% | 8,300,000 | 0.0% | 13.76% | +36.1% | ||
| NUVALENT INC | $93,331 | -12.4% | 3,577,267 | 0.0% | 11.66% | -2.0% | ||
| SWTX | Sell | SPRINGWORKS THERAPEUTICS INC | $79,313 | -36.9% | 3,081,307 | -36.2% | 9.91% | -29.4% |
| New | DISC MEDICINE INC | $42,187 | – | 1,990,914 | +100.0% | 5.27% | – | |
| NTRA | Sell | NATERA INC | $38,875 | -30.9% | 700,197 | -50.0% | 4.86% | -22.7% |
| DVAX | DYNAVAX TECHNOLOGIES CORP | $38,406 | -7.8% | 3,915,000 | 0.0% | 4.80% | +3.1% | |
| CRNX | CRINETICS PHARMACEUTICALS IN | $37,027 | -12.2% | 2,305,558 | 0.0% | 4.63% | -1.8% | |
| MRSN | MERSANA THERAPEUTICS INC | $35,608 | -29.9% | 8,663,673 | 0.0% | 4.45% | -21.6% | |
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $33,000 | -25.7% | 3,000,000 | 0.0% | 4.12% | -16.9% | |
| ACRS | New | ACLARIS THERAPEUTICS INC | $27,506 | – | 3,400,000 | +100.0% | 3.44% | – |
| PHVS | PHARVARIS N V | $25,620 | -28.4% | 3,180,601 | 0.0% | 3.20% | -19.9% | |
| SVRA | SAVARA INC | $22,664 | +25.8% | 11,622,598 | 0.0% | 2.83% | +40.7% | |
| CBAY | New | CYMABAY THERAPEUTICS INC | $21,800 | – | 2,500,000 | +100.0% | 2.72% | – |
| CTIC | Buy | CTI BIOPHARMA CORP | $19,753 | -13.0% | 4,702,996 | +24.5% | 2.47% | -2.7% |
| EQRX INC | $19,407 | -21.1% | 10,003,573 | 0.0% | 2.43% | -11.8% | ||
| ANNX | ANNEXON INC | $18,813 | -25.5% | 4,886,616 | 0.0% | 2.35% | -16.7% | |
| NRIX | NURIX THERAPEUTICS INC | $16,187 | -19.1% | 1,822,883 | 0.0% | 2.02% | -9.6% | |
| SOLID BIOSCIENCES INC | $14,838 | -11.9% | 3,130,422 | 0.0% | 1.85% | -1.5% | ||
| 2SEVENTY BIO INC | $14,371 | +8.9% | 1,408,901 | 0.0% | 1.80% | +21.8% | ||
| RAPID MICRO BIOSYSTEMS INC | $11,049 | +15.9% | 8,434,560 | 0.0% | 1.38% | +29.7% | ||
| CARA | Sell | CARA THERAPEUTICS INC | $10,824 | -62.6% | 2,204,449 | -18.2% | 1.35% | -58.2% |
| XFOR | X4 PHARMACEUTICALS INC | $10,616 | -12.4% | 12,202,510 | 0.0% | 1.33% | -2.0% | |
| MARINUS PHARMACEUTICALS INC | $9,874 | +73.3% | 1,431,058 | 0.0% | 1.23% | +93.7% | ||
| XILIO THERAPEUTICS INC | $8,893 | +17.8% | 2,805,413 | 0.0% | 1.11% | +31.8% | ||
| AVIR | ATEA PHARMACEUTICALS INC | $8,327 | -30.4% | 2,485,638 | 0.0% | 1.04% | -22.1% | |
| TANGO THERAPEUTICS INC | $7,591 | -45.5% | 1,921,790 | 0.0% | 0.95% | -39.0% | ||
| SYROS PHARMACEUTICALS INC | $5,673 | -25.6% | 2,124,694 | 0.0% | 0.71% | -16.8% | ||
| NAUT | NAUTILUS BIOTECHNOLOGY INC | $5,540 | +53.9% | 2,000,000 | 0.0% | 0.69% | +72.1% | |
| CCCC | C4 THERAPEUTICS INC | $5,157 | -46.8% | 1,642,210 | 0.0% | 0.64% | -40.4% | |
| Sell | THIRD HARMONIC BIO INC | $2,639 | -46.7% | 640,631 | -44.4% | 0.33% | -40.3% | |
| INVIVYD INC | $2,325 | -20.0% | 1,937,207 | 0.0% | 0.29% | -10.5% | ||
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $1,551 | -35.5% | 5,347,689 | 0.0% | 0.19% | -27.9% | |
| APTX | APTINYX INC | $1,110 | -56.2% | 8,891,758 | 0.0% | 0.14% | -51.1% | |
| NEWAMSTERDAM PHARMA COMPANY*w exp 11/22/202 | $184 | +114.0% | 100,000 | 0.0% | 0.02% | +130.0% | ||
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -701,402 | -100.0% | -1.25% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -2,364,410 | -100.0% | -2.88% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, L.P. #2
- BC SW, LP #3
- Bain Capital Life Sciences Investors II, LLC #4
- Bain Capital Life Sciences Fund II, L.P. #5
- BCLS II Investco (GP), LLC #6
- BCLS II Investco, LP #7
- Bain Capital Life Sciences III General Partner, LLC #8
- Bain Capital Life Sciences Fund III, L.P. #9
- Bain Capital Life Sciences Opportunities III GP, LLC #10
- Bain Capital Life Sciences Opportunities III, LP #11
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APTINYX INC | 20 | Q1 2023 | 16.9% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
| SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
| DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
| DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
| SAVARA INC | 16 | Q3 2023 | 6.0% |
| X4 PHARMACEUTICALS INC | 16 | Q3 2023 | 3.2% |
| ARCUTIS BIOTHERAPEUTICS, INC. | 15 | Q3 2023 | 20.1% |
| MERSANA THERAPEUTICS, INC. | 14 | Q3 2023 | 8.4% |
| CRINETICS PHARMACEUTICALS, INC. | 14 | Q3 2023 | 5.4% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 3 | 2024-02-07 |
| 4 | 2024-01-12 |
| 3 | 2023-12-29 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-05-30 |
| 4 | 2023-05-30 |
| 13F-HR | 2023-05-15 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.